Metreleptin
- Generic Name
- Metreleptin
- Brand Names
- Myalept, Myalepta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 186018-45-1
- Unique Ingredient Identifier
- TL60C27RLH
- Background
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with congenital or acquired lipodystrophy. Affecting less than 500 people worldwide, lipodystrophy is characterized by a lack of adipose tissue, fat deposition in the muscles and liver, and metabolic complications such a...
- Indication
Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
- Associated Conditions
- Congenital leptin deficiency
- Associated Therapies
- -
Pharmacokinetics of Leptin Administration During Fasting
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00140205
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
- Conditions
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00130117
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center General Clinical Research Center, Boston, Massachusetts, United States
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2023-06-13
- Target Recruit Count
- 11
- Registration Number
- NCT00085982
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Leptin to Treat Lipodystrophy
- First Posted Date
- 2001-10-28
- Last Posted Date
- 2016-08-16
- Target Recruit Count
- 103
- Registration Number
- NCT00025883
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.